Probiotics' brain benefits pass a strict evidence audit

Probiotics are one of the most heavily marketed supplement categories, and a stack of pooled trial analyses has claimed benefits across many health conditions. What nobody had done, according to these authors, was step back and grade the overall strength and calibre of that evidence. That grading matters because a statistically significant result built on a couple of small trials deserves far less confidence than one resting on consistent, well-conducted studies. The gut-brain territory in particular attracts bold claims, so an honest quality audit is overdue.

The researchers ran an umbrella review, a study of studies, searching PubMed, Embase, Web of Science, Scopus and the Cochrane database from their starting dates until 20 April 2024. They included meta-analyses of randomised controlled trials that tested probiotics in adults. For every association reported, they extracted the effect estimates and recalibrated the effect sizes. Each association was then graded using the GRADE framework, which sorts evidence into high, moderate, low or very low quality.

Seventeen meta-analyses qualified, drawing on 156 randomised trials, of which 51 were unique studies. Individual trials ranged from 37 to 409 participants, with follow-up from 0.5 to 28 weeks. Of 106 associations examined, 47 were nominally statistically significant, and among those, 18 were graded as high quality evidence, 18 as moderate, 10 as low and 1 as very low. Cognitive function accounted for 21 of the significant associations, with the rest spread across blood glucose, lipid profiles, oxidative stress markers, inflammatory markers and other indicators.

This is presented as the first synthesis of the overall strength of probiotic evidence in this space, and it lands more favourably than sceptics might expect: the cognitive associations came out with moderate to high quality backing. That said, the median number of studies behind each association was just 3, and the trials themselves were small and short. The authors are explicit that further clinical trials are needed to pin down which probiotic strains, doses and intervention durations actually drive the outcomes. Until then, the field knows the direction better than the details.

If you already take a probiotic, this review is a reason to regard the cognitive angle as more than marketing, since the evidence behind it graded reasonably well by a strict standard. It is not a reason to expect a noticeable change in your own thinking, because the trials were small, short and varied in what they tested. Anyone weighing up a purchase should know that no particular strain, dose or duration has been singled out as the effective one. The honest summary is a credible signal with the practical specifics still missing.